East China Observational Study Aims to Identify High-Risk T2D Patients for GLP-1 RA Intervention

Type 2 Diabetes (T2D) patients face elevated atherosclerotic cardiovascular disease (ASCVD) risk, a leading cause of morbidity and mortality. While Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce major adverse cardiovascular events (MACE) in T2D, specific evidence for elderly populations, who are at particularly high CV risk, remains limited. This gap highlights the need for better risk stratification and targeted interventions, especially in diverse patient cohorts. The SOUL trial, for instance, showed oral semaglutide reduced MACE by 14%, underscoring the potential of GLP-1 RAs.

This is an observational study conducted in East China, aiming to identify Type 2 Diabetes patients at high risk for atherosclerotic cardiovascular disease (ASCVD). The study's design involves screening these high-risk individuals and subsequently observing their outcomes with or without Glucagon-like peptide-1 receptor agonist (GLP-1 RA) interventions. The primary objective is to evaluate the effectiveness of GLP-1 RAs in a real-world setting for this specific patient population, particularly focusing on risk stratification and intervention strategies.